The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Catheter with specialized nanosensors could enable earlier detection of bladder cancer, MIT study finds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE

While treatment is often successful, bladder cancer has one of the highest rates of recurrence of any cancer: Following treatment, about 50% of patients develop tumors again within the next five years. This makes it one of the most expensive cancers for society to treat.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Clinical Roundup

Imfinzi regimen reduced early disease recurrence in non-muscle-invasive bladder cancer, phase III trial POTOMAC shows

Exploratory analyses of the POTOMAC phase III trial showed adding one year of treatment with AstraZeneca’s Imfinzi (durvalumab) to BCG induction and maintenance therapy reduced the number of high-risk disease recurrences within the first year, with fewer BCG-unresponsive recurrences in patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer compared to BCG treatment alone.
Clinical Roundup

Perioperative Imfinzi + neoadjuvant EV improved EFS and OS in muscle-invasive bladder cancer, phase III VOLGA trial shows

High-level results from a planned interim analysis of the VOLGA phase III trial showed perioperative treatment with Imfinzi (durvalumab) in combination with neoadjuvant enfortumab vedotin demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survival in patients with muscle-invasive bladder cancer versus standard of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account